Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nuvalent ( (NUVL) ) has issued an update.
On June 9, 2025, Emily Conley, a member of the board of directors at Nuvalent, Inc., announced her resignation from the board and all its committees, effective at the company’s 2025 annual stockholders’ meeting. Her resignation was not due to any disagreements with the company’s operations, policies, or practices.
The most recent analyst rating on (NUVL) stock is a Buy with a $125.00 price target. To see the full list of analyst forecasts on Nuvalent stock, see the NUVL Stock Forecast page.
Spark’s Take on NUVL Stock
According to Spark, TipRanks’ AI Analyst, NUVL is a Neutral.
Nuvalent’s overall score reflects the typical high-risk, high-reward nature of early-stage biotech firms. Strengths include a solid cash position and no debt, while significant risks arise from the lack of revenue and dependency on external financing. Technical indicators suggest positive short-term momentum, but overbought conditions may present challenges. Valuation metrics are not favorable due to negative earnings.
To see Spark’s full report on NUVL stock, click here.
More about Nuvalent
Average Trading Volume: 591,726
Technical Sentiment Signal: Buy
Current Market Cap: $5.6B
Find detailed analytics on NUVL stock on TipRanks’ Stock Analysis page.